Multiscale, mechanistic model of Rheumatoid Arthritis to enable decision making in late stage drug development

• Published in: NPJ systems biology and applications Vol. 10; no. 1; pp. 126 - 22
• Main Authors: Bedathuru, Dinesh, Rengaswamy, Maithreye, Channavazzala, Madhav, Ray, Tamara, Packrisamy, Prakash, Kumar, Rukmini
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.11.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/250; 631/553/2696; Adalimumab - therapeutic use; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - pharmacology; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - drug therapy; Autoimmune diseases; Bioinformatics; Biomedical and Life Sciences; Clinical trials; Computational Biology/Bioinformatics; Computer Appl. in Life Sciences; Decision Making; Drug development; Drug Development - methods; Humans; Inflammatory diseases; Life Sciences; Methotrexate; Methotrexate - therapeutic use; Models, Biological; Monoclonal antibodies; Rheumatoid arthritis; Rheumatology; Systems Biology; Tumor necrosis factor-α

Rheumatoid Arthritis (RA) is a chronic autoimmune inflammatory disease that affects about 0.1% to 2% of the population worldwide. Despite the development of several novel therapies, there is only limited benefit for many patients. Thus, there is room for new approaches to improve response to therapy...